Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 4/20 | 0.42 |
| ▸ | NT5E | P21589 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6258361 | 1.00 | ADORA3 (0.57) | ADORA3ADORA1ADORA2AADORA2BALDH1A1 | |
| SCHEMBL6258364 | 1.00 | ADORA3 (0.57) | ADORA3ADORA1ADORA2AADORA2BALDH1A1 | |
| SCHEMBL6262450 | 0.90 | ADORA3 (0.57) | ADORA3ADORA1ADORA2AADORA2BACHE | |
| SCHEMBL6262448 | 0.90 | ADORA3 (0.57) | ADORA3ADORA1ADORA2AADORA2BACHE | |
| SCHEMBL6262446 | 0.90 | ADORA3 (0.57) | ADORA3ADORA1ADORA2AADORA2BACHE | |
| SCHEMBL6262050 | 0.88 | ADORA3 (0.48) | ADORA3ADORA1ADORA2AADORA2BALDH1A1 | |
| SCHEMBL6262046 | 0.88 | ADORA3 (0.48) | ADORA3ADORA1ADORA2AADORA2BALDH1A1 | |
| SCHEMBL6262051 | 0.88 | ADORA3 (0.48) | ADORA3ADORA1ADORA2AADORA2BALDH1A1 | |
| SCHEMBL6573858 | 0.85 | ALDH1A1 (0.66) | ADORA3ADORA1ADORA2AADORA2BALDH1A1 | |
| SCHEMBL6573849 | 0.85 | ALDH1A1 (0.66) | ADORA3ADORA1ADORA2AADORA2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370568-B1 | CHEMICAL COMPOUNDS | GLAXO GROUP LTD (GB) | 2005-10-12 | — | — | EP | disclosed |
| US-20040162422-A1 | adenosine derivatives having an acetylene group in the 4' position, which are adenosine A1 agonists; treating ischaemic heart disease, peripheral vascular disease or stroke or patient suffering pain, a CNS disorder, sleep apnoea or emesis | HALL ADRIAN (GB) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162422-A1 | adenosine derivatives having an acetylene group in the 4' position, which are adenosine A1 agonists; treating ischaemic heart disease, peripheral vascular disease or stroke or patient suffering pain, a CNS disorder, sleep apnoea or emesis | ADORA1, ADORA2A, ADORA2B | ADORA3 4/4885ADORA1 1/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.